{"page_content": "ESG Report 2023\nAt Agios, we are committed to building a sustainable business that provides long-\nterm value for all our stakeholders. We support environmental, social and governance \n(ESG) initiatives that are aligned with our culture and values and that may positively impact the patients we serve, our employees, our communities and our world.\nThis document contains disclosure of sustainability metrics relevant to Agios\u2019 \nbusiness and strategy. These metrics are aligned with the Sustainability Accounting Standards Board (SASB) standards for the Biotechnology and Pharmaceuticals Industry and the United Nations Sustainable Development Goals (UN SDGs). Unless otherwise noted, it covers ESG disclosures for Agios Pharmaceuticals for the period Jan. 1, 2022 through Dec. 31, 2022.\nAgios Pharmaceuticals \nCorporate Sustainability  Tear Sheet\n    Ian Rosenblum,  \nVice President, IT and Facilities2", "metadata": {"source": "NASDAQ_AGIO_2022.pdf", "page": 1, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}